A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy
NCT03862846
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
23
Enrollment
INDUSTRY
Sponsor class
Stopped
COVID-19 Pandemic sufficient data gathered to achieve the study objective
Conditions
Primary Mitochondrial Myopathy
Interventions
DRUG:
REN001
Sponsor
Reneo Pharma Ltd